Neuronetics (FRA:NRC) Research & Development: €5.4 Mil (TTM As of Mar. 2026)


FRA:NRC Neuronetics Inc FRA:NRC
51 GF Score
Price €1.07
GF Value €1.65
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Neuronetics Research & Development?

Neuronetics FRA:NRC +1.42% 51 Research & Development is €5.4 Mil as of Mar. 2026. GuruFocus rates FRA:NRC with a GF Score™ of 51/100 and a GF Value™ of €1.65 (Possible Value Trap). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Neuronetics's Research & Development for the three months ended in Mar. 2026 was €1.2 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €5.4 Mil.

Neuronetics  (FRA:NRC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Neuronetics Research & Development Related Terms

Neuronetics Research & Development Historical Data

* Premium members only.

The historical data trend for Neuronetics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuronetics Research & Development Chart

Neuronetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.01 8.81 8.73 12.20 5.62

Neuronetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.50 1.56 1.28 1.42 1.18
FRA:NRC
51GF Score
Neuronetics Inc FRA:NRC
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuronetics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €5.4 Mil mean?
Neuronetics (FRA:NRC) has a Research & Development of €5.4 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Neuronetics and its competitors.
Is Neuronetics' Research & Development too high?
Neuronetics' current Research & Development is €5.4 Mil. Overall, Neuronetics has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Neuronetics' Research & Development compare to ZOMDF and RPID?
Neuronetics' Research & Development of €5.4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Neuronetics and its competitors. Neuronetics's current Research & Development is €5.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuronetics stock overvalued right now?
Based on GuruFocus' analysis, Neuronetics (FRA:NRC) is currently considered Possible Value Trap. The stock's GF Value™ is €1.65, compared to a current price of €1.07 — trading 35.2% below its estimated fair value. The current Research & Development is €5.4 Mil. Neuronetics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Neuronetics (FRA:NRC), the current Research & Development is €5.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuronetics (FRA:NRC) Overvalued in 2026?

Based on GuruFocus' analysis, Neuronetics stock appears to be undervalued. The current stock price of €1.07 is trading 35.2% below its estimated GF Value™ of €1.65. GuruFocus considers Neuronetics to be Possible Value Trap.

Key valuation signals for FRA:NRC:

  • Research & Development: €5.4 Mil
  • GF Value™: €1.65 vs. price of €1.07 (35.2% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the FRA:NRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuronetics Business Description

Other Exchanges STIM:USA
Address 3222 Phoenixville Pike, Malvern, PA, USA, 19355
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
51GF Score

Get the complete analysis for FRA:NRC

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.07
Price
€1.65
GF Value